Detailed analysis of TOP20 global pharmaceutical companies by revenue in 2020!

Fierce Pharma《2020TOP20》。

Fierce Pharma《2020TOP20》2020。

01

COVID-192020，，COVID-19。0.

，，8%，456，。

1.

Stelara，，77，21%。，，。，Tremfya33%，13.

，，Remicade14%，37.

2021，10COVID-19，。

2021888，。10，2021100。

02

、、2020。

2020，40。，，57，、50.

Bill Anderson2，2021，46。

Ocrevus2020。44.

PD-L1Tecentriq，55%，202027.

，3FDA。20207，7.

，LucentisVEGFxAng2faricimab23Eylea。1.

COVID-19，IL-6Actemra，（CRS）。COVID-19，Actemra202032%，28.

COVID-19，，14%。202015COVID。，8%，445.

03

202097TMC，FDAPCSK9inclisiran，COVID-19。12，inclisiran，，。

Inclisiran is not the only time Novartis has suffered a regulatory setback last year.

When Zolgensma's intrathecal preparation encountered difficulties, Roche launched a new oral preparation, Evrysdi, for SMA patients 2 months and older.

Thanks to EU approval and Japan’s May reimbursement decision, Zolgensma’s sales in 2020 reached 920 million U.

Novartis has achieved several victories in 2020 by converting the anticancer drug ofatumumab into an FDA-approved multiple sclerosis treatment drug, which is now sold under the Kesimpta brand.

So far, Kesimpta has been slow to market, and Ocrevus's growth has slowed.

In addition to Kesimpta, Novartis also received US FDA approval in May 2020 for Tabrecta to treat non-small cell lung cancer (NSCLC) patients with MET exon 14 skip mutations, which account for 3% of newly diagnosed NSCLC cases-4 %.
This approval is 9 months ahead of Merck's competitive product Teppetko in the same indications in the United States.

Cosentyx is currently Novartis’s best-selling drug, with sales of 4 billion U.
S.
dollars in 2020.
In this year, the drug added radiology-negative axial spondyloarthritis (nr-axSpA) to the label.
Competitive IL-17 product Taltz is on par.

Entresto is another key growth engine for Novartis.
It recently received an approval from the US FDA to expand its treatment indications to heart failure with preserved ejection fraction (HFpEF).
According to estimates by Novartis, sales of the drug will increase by 44% year-on-year to US$2.
5 billion.
With new indications, Novartis expects that peak sales of the drug will increase by US$1 billion, reaching about US$4 billion to US$5 billion.

04 Merck

In 2020, when COVID-19 is raging, Merck still achieved a strong performance of US$48 billion in revenue.
Sales increased by 2.
5%, but compared with the upward trend of revenue growth of 11% in 2019, it is not comparable.

As of late October 2020, Merck has adjusted its estimated COVID-19 pandemic risk of US$1.
9 billion to US$2.
5 billion.
If this part of the lost revenue is added to the sales figures in 2020, a healthy growth of 8% can be achieved.

Merck’s strong performance is attributed to the immuno-oncology superstar Keytruda, whose sales in 2020 reached 14.
4 billion US dollars, an increase of 30%, making it the world’s best-selling drug in the next few years.
Sales of the hypoglycemic drug Januvia were US$5.
3 billion, a decrease of 4% from 2019.
Sales of the diabetes compound Janumet also declined slightly, to US$2 billion.

HPV vaccine Gardasil sales of 3.
9 billion US dollars, an increase of 5% over 2019, and an increase of 19% in 2019.

Merck’s other higher-income products include varicella vaccine Varivax (US$1.
9 billion), Bridian (US$1.
2 billion) and Pneumovax (US$1.
1 billion).

At present, Merck will continue to work hard to get rid of its dependence on Keytruda in order to achieve diversification.
In November last year, the company acquired VelosBio, which is studying therapies against the ROR1 target.
Merck also hopes to achieve better results than the acquisition of Themis.
In May last year, Merck acquired Themis and formally joined the COVID-19 vaccine research and development ranks.
However, in January this year, due to the unsatisfactory antibody titer of the vaccine, the development of two vaccines V590 and V591 was stopped.

05 AbbVie

The COVID-19 pandemic has made Allergan's medical beauty business a difficult year.
For example, Botox dropped by 43% from the second quarter of 2019 to the same period last year.
But under AbbVie's leadership, the anti-wrinkle formula rebounded in less than eight months, generating $2.
5 billion in revenue.
If this figure is calculated annually within 12 months, this performance is equivalent to the $3.
8 billion in revenue that Botox brought to Allergan in 2019.

Many of Allergan's products have performed well, among which Vraylar is the first.
This antidepressant has brought AbbVie's benefits (US$951 million) in less than 8 months more than the entire year of 2019 (US$858 million).
If calculated over a whole year, the figures of Restasis ($787 million) and Linzess ($667 million) exceeded their performance in 2019 under Allergan’s leadership.

Immunology is still AbbVie's main source of income.
The flagship product Humira (Humira, $19.
8 billion) may experience a brilliant decline.
But it still rebounded (increased by 3.
5%) from 2019 (down 4%).
At the same time, the new anti-inflammatory drug Skyrizi ($1.
6 billion) for plaque psoriasis and Rinvoq ($730 million) for rheumatoid arthritis have shown their potential as the ultimate successor.

Sales of blood cancer drugs Imbruvica (US$5.
3 billion) and Venclexta (US$1.
3 billion) were strong, with the latter's figures increasing 69% from 2019.

Also above the $1 billion mark are Mavyret ($1.
8 billion) and Creon ($1.
1 billion).
Mavyret used to be a budding superstar, but now is declining rapidly like most other hepatitis C drugs.

AbbVie's acquisition of Allergan certainly played a role in the jump in valuation, but at the same time it also played a role in the huge potential of the rising stars of immunology Skyrizi and Rinvoq.
AbbVie estimates that by 2025, the annual revenue of these two products will reach 15 billion U.
S.
dollars.

The company also has some promising drugs in development, including the drug ABBV-951 for the treatment of Parkinson's disease, elezanumab for the treatment of spinal cord injury and some tumor drug candidates.

06 GlaxoSmithKline

GSK played a supporting role in the early race to develop an effective COVID-19 vaccine, providing adjuvants to improve the effectiveness of vaccine candidates from other companies, rather than developing its own vaccine.

Unfortunately, GSK's existing vaccines and its COVID vaccine efforts were affected during the pandemic, resulting in its sales being flat year-on-year.

The most prominent adjuvant cooperation agreement signed by GSK and Sanofi is a recombinant protein-based COVID vaccine.
In December last year, in a Phase 1/2 study conducted in people aged 50 and over, this vaccine failed to trigger enough After a strong immune response, the partner was forced to readjust the formula.
A few weeks ago, a new phase 2 study was launched, and there may be a phase 3 study in the second quarter.

At the same time, GSK’s existing vaccines have been hit hard because consumers have postponed routine vaccination during the pandemic.
Its vaccine growth engine, the shingles vaccine Shingrix, achieved a 10% growth in 2020, with sales reaching 1.
99 billion pounds, but this was disappointing because the demand for the vaccine had exceeded before the COVID-19 pandemic The supply.
And this is not enough to offset the 15% drop in total sales of its old-brand vaccines, which will generate a total of 3.
23 billion pounds in 2020.

As COVID-19 vaccination is currently being prioritized, GSK expects that Shingrix's slowdown will last at least until the first half of 2021, and there will be no real rise until 2022.

GSK does have some bright spots in 2020, including its respiratory system product line.
The revenue of the triple inhaler Trelegy was 819 million pounds, a year-on-year increase of 58%.

Another driving factor for the growth of GSK's respiratory system, Nucala's revenue was 994 million pounds, a year-on-year increase of 29%.
Last year, Nucala received FDA approval to treat a rare disease called eosinophilia syndrome.
GSK also applied to the FDA for approval of Nucala as a drug for the treatment of chronic sinusitis with nasal polyps.

HIV is another pillar of the GSK Pharmaceutical franchise.
In 2020, HIV business sales will remain flat at 4.
88 billion.

GSK also vigorously promoted tumor research and development, but this effort did not produce high returns.
PARP inhibitor Zejula's sales in 2020 increased by 48% year-on-year to 339 million pounds.

In terms of consumer health, GSK has been busy integrating its investment portfolio with Pfizer, and is committed to the implementation of the divestiture plan to prepare for the planned spin-off in 2022.
In 2020, sales of vitamins and food supplement franchises in the consumer healthcare business have increased by more than 10%.

07 Bristol-Myers Squibb

In 2020, Bristol-Myers Squibb (BMS) sales jumped by US$16 billion from 2019.
This is the result of a transformation that began in November 2019, when BMS and Xinji initiated a $74 billion merger and acquisition.

Celgene’s annual sales increased BMS’s revenue by 63%.
The best-selling product was Revlimid, an anticancer drug from Celgene, with sales of $12.
1 billion, an increase of 12% over the previous year.

Other top performers are Orencia ($3.
2 billion), Sprycel ($2.
1 billion), Yervoy ($1.
7 billion) and Abraxane ($1.
2 billion).
Eliquis' sales increased by 16% to $9.
2 billion, thanks to data showing that this blood thinner can reduce the risk of stroke and heart attack in COVID-19 patients.

But some BMS drugs struggled last year.
As PD-1 inhibitors continue to face fierce competition from Merck’s Keytruda, Opdivo’s sales fell by 3% to $7 billion.
There are also disappointments in some studies, including a study showing that combined chemotherapy is not as effective as chemotherapy alone in the treatment of non-squamous non-small cell lung cancer.

BMS investors know that because the multiple myeloma drug Revlimid will face generic competition in early 2022, the company cannot rely on it for a long time.

Although Revlimid is about to lose its exclusive rights, some analysts are still predicting the bright future of BMS.
Evaluate Pharma predicts that by 2026, Eliquis will be the world's second best-selling drug and Opdivo will be the third best-selling drug.

Last year, BMS also received FDA approval for the multiple sclerosis drug Zeposia, which will be launched after the pandemic.

Fighting Merck Keytruda will be a difficult task.
But analysts say that because the FDA approved two approvals for the combination with Yervoy last year, Opdivo should have room for growth.

08 Pfizer

Although Pfizer has won praise for its successful development and launch of the first COVID-19 vaccine with its partner BioNTech in 2020, its performance has been affected by a series of other events and products.

Due to the spin-off of its generic drug business Upjohn, Pfizer fell from No.
3 in the TOP20 last year to No.
8 this year.
Upjohn merged with Mylan to create a new company, Viatris, which officially passed the FTC in November 2020.
This is also the time when Upjohn's income is cleared from Pfizer's books.

In 2020, Pfizer’s total revenue was US$41.
9 billion.
If Upjohn’s performance is excluded, it would increase by 2% compared to last year.

Pfizer reported that due to the strong growth of multiple drugs such as Vyndaqel, Eliquis, Ibrance, Xeljanz and Xtandi, the company's operating income increased by 8% in 2020.
The strong performance helped offset the decline in sales of Enbrel, Prevnar 13, and Chantix.

The biggest increase was the prostate cancer drug Xtandi, which increased by 22% and entered the ranks of blockbuster products with sales of US$1.
02 billion.
Eliquis grew by 17% to $4.
95 billion, and Ibrance grew by 9%, with annual sales of $5.
39 billion.

Among the underperforming drugs, Enbrel sales fell 21% to $1.
35 billion, and Chantix sales fell 17% to $919 million.

Sales of Pfizer's blockbuster vaccine Prevnar13 were flat year-on-year, but still contributed $5.
85 billion.
The COVID-19 vaccine Comirnaty achieved $154 million in sales after receiving emergency approval in December last year.

Pfizer recently adjusted its estimated sales for 2021 to between 59.
4 billion and 61.
4 billion U.
S.
dollars, and it is expected that COVID-19 vaccine sales this year will reach approximately 15 billion U.
S.
dollars.

With the merger of Viatris' generic drug business and the previous merger with GSK's consumer business, Pfizer plans to use its mRNA experience for future discoveries.

09 Sanofi

Last year, in the challenges brought about by the COVID-19 pandemic, Sanofi’s new “Play to Win” strategy [required to focus on Sanofi’s successful products and therapeutic areas, including immunology, among which there are important Pound products Dupixent and vaccines] began to pay off.
For example, in the third quarter alone, Dupixent drove more than $1 billion in sales, an increase of 69% over the same period last year.

Influenza vaccines have provided Pfizer with record sales, reaching 1.
07 billion euros in the third quarter, as the COVID-19 pandemic has made influenza vaccination a top priority for people all over the world.

In total, Sanofi’s sales in 2020 increased by 3.
3% to 36 billion euros.
Dupixent alone generated a total revenue of 3.
5 billion euros, while sales of oncology soared 27% to 798 million euros, driven by the launch of Sarclisa and Libtayo and the growth of old drugs.

On the other hand, Sanofi's sales of diabetes and cardiovascular drugs, which have had a strong performance in the past, have fallen again.
At a constant exchange rate, the company's diabetes sales fell 4.
8% to 4.
7 billion euros.
Cardiovascular and mature medicine revenue fell by 8.
8% to 10 billion euros.

Sanofi's new strategy also includes cutting costs.
In February of this year, when the company announced its 2020 full-year results, executives said that Sanofi had squeezed out 1.
7 billion euros in costs, approaching the goal of cutting 2 billion euros in 2022.
The company has reinvested 60% of the savings.
Since it has achieved high levels of savings, the company has added another 500 million euros to its 2022 target.

10 Takeda

In 2020, Takeda achieved its previously set goal of divesting US$10 billion in products to reduce the debt burden caused by the acquisition of Shire.

As a result of these transactions, Takeda reduced its net debt/adjusted EBITDA ratio to 3.
6 times at the end of 2020, which is closer to its deleveraging target of 2 times before the fiscal year 2023 (end of March 2024).
Entering 2021, the divestiture boom seems to be very active.

Takeda is focused on finding new growth opportunities for prescription drugs, focusing on the best-selling inflammatory bowel disease drug Entyvio.
In 2020, Entyvio's revenue was 403 billion yen (approximately US$3.
77 billion), a year-on-year increase of 21.
5%.

Takeda's oncology portfolio will have joys and setbacks in 2020.
Alunbrig has been approved by the US FDA for the treatment of previously untreated ALK-positive non-small cell lung cancer patients.
The problem is that sales in the 2020 calendar year are only 8.
6 billion yen (80 million US dollars).

Sales of the blood cancer drug Velcade continued to decline due to the loss of market exclusivity.
Its sales of 75.
9 billion yen (US$720 million) from April to December were down 16.
4% from the same period in 2019.

The company hopes that some newer cancer drugs, such as Velcade follow-up drug Ninlaro, Seagen-licensed antibody conjugate Adcetris, leukemia drug Iclusig, and ALK lung cancer drug Alunbrig, can fill this gap.

In terms of COVID-19 drugs, Takeda’s work has focused on a highly immunoglobulin product called CoVIg-19, which is made by concentrating plasma donated by patients who have recovered from COVID-19.

In addition, Takeda is testing the intravenous formulation of its hereditary angioedema drug Firazyr and its follow-up drug Takhyzro in two phase 3 platform trials.
It is hoped that one of these two drugs can help control the dangerous inflammatory response of some COVID patients.

More importantly, Takeda has signed a contract to help vaccine developers bring their vaccines to Japan.
It will help distribute Moderna's mRNA vaccine and will develop, manufacture and sell Novavax's nanoparticle vaccine NVX-CoV2373 in Japan.

Also in terms of vaccines, Takeda plans to apply for approval of its dengue vaccine TAK-003 soon.
Among more than a dozen new drugs planned to be launched before fiscal 2024, Takeda said that one drug may bring peak sales of more than 10 billion U.
S.
dollars.

11 AstraZeneca

AZ achieved double-digit sales growth amid the COVID-19 pandemic, partly because only two of its top ten best-selling drugs were used in medical institutions.
The company is also one of the few companies authorized to obtain a COVID-19 vaccine, and it also signed the world's largest M&A transaction for biopharmaceuticals in 2020.

PD-L1 inhibitor Imfinzi is one of the two TOP drugs used in medical institutions in the AZ product portfolio, and has achieved stable revenue growth.
The drug was approved for the first time in 2017, and revenue increased by 39% to reach 2.
04 billion U.
S.
dollars.
Most of the revenue and growth potential came from the application in stage 3 non-small cell lung cancer.

In AZ's product portfolio, the old-brand asthma drug Pulmicort (inhaled budesonide) is another top drug used in medical institutions.
In 2019, the drug is still growing by a double-digit percentage, but COVID-19 has led to a sharp decrease in the number of patients visiting the nebulization center.
This led to a sharp drop in Pulmicort's revenue last year, with sales falling 32% to US$996 million.

In addition to Imfinzi, the lung cancer targeted drug Tagrisso and the PARP inhibitor Lynparza, which is cooperating with Merck & Co.
, these two drugs are important driving forces that drove AZ's product sales last year to increase by 10% year-on-year to US$25.
89 billion.
Tagrisso's sales increased by 36% to 4.
33 billion US dollars, while Lynparza increased by 48% to 1.
78 billion US dollars.

These drugs form the backbone of AZ's business, but public attention to the company has recently focused on its COVID-19 vaccine AZD1222.
Recently, concerns about AZ vaccine caused by venous thrombosis in a small number of vaccinators have led to a suspension of vaccination in several European countries.

In the whirlwind of the COVID vaccine crisis, AZ announced the world's largest acquisition of biopharmaceuticals in 2020, and plans to acquire rare disease company Alexion for US$39 billion.
The deal gave AZ some listed drugs, mainly complement inhibitors Soliris and Ultomiris.
In 2020, Alexion achieved sales of US$6.
07 billion, an increase of 21.
6% over 2019.

12 Bayer

Fierce Pharma’s annual pharmaceutical ranking does not cover Bayer’s crop science business.
In terms of pharmaceuticals, the best-selling drugs Eylea and Xarelto are facing a patent cliff.
In January of this year, the company announced new data showing that using Nubeqa to treat prostate cancer based on androgen deprivation therapy (ADT) can prolong the lives of patients.

In the same month, some not-so-good news eased this positive interpretation.
Cost monitoring agencies in the UK and Germany rejected Bayer’s “tumor-agnostic” anti-cancer drug Vitrakvi due to price and data restrictions.
.

Like many drugmakers, Bayer performed better than expected in the first quarter at the beginning of 2020, thanks in large part to Xarelto's inventory increase.

While Bayer performed strongly in the first quarter, it also experienced a slowdown in the second quarter, a situation familiar to many companies during the COVID-19 pandemic.
Despite this, the ophthalmic drug Eylea remained strong, with sales falling only 6%, which is much smaller than the 25% decline in sales of Roche and Novartis' rival Lucentis.
Also in the second quarter, thanks to sales growth in China, Russia and Germany, Xarelto sales increased by 5%.

Excluding Bayer's crop science business, the company's 2020 revenue was 22.
56 billion euros (25.
71 billion U.
S.
dollars), slightly lower than the 23.
71 billion euros (26.
59 billion U.
S.
dollars) in 2019.
Total pharmaceutical sales fell by 1.
5% to 17.
24 billion euros.
Bayer said that COVID-19 restrictions are particularly detrimental to its ophthalmology and women's health businesses, especially in the first half of 2020.

At the same time, Bayer is trying to participate in the fight against COVID-19 in 2020, even though its donated 3 million tablets of antimalarial drug hydroxychloroquine turned out to be unlucky.
At the beginning of this year, the company said it would help German compatriot CureVac to bring its developed mRNA vaccine to the market.

In other respects, Bayer has been working on the restructuring plan announced in 2018.
In July 2020, the company obtained an antitrust license for the US$7.
6 billion acquisition of animal health company Elanco, and the company said in October that the pressure of COVID-19 will force additional cost cuts of more than 1.
5 billion euros (1.
8 billion euros) by 2024.
US dollars).

13 Amgen

Amgen’s core products Neulasta, Neuupogen, and Sensipar all lost market exclusivity in 2019, but the company also made several attempts of its own in the field of biosimilar drugs, and it paid off last year.
In addition, Amgen has recently launched some strong new products and is expected to succeed in the pipeline.

Due to the huge sales growth of key products, Amgen achieved a revenue growth of 7% in 2020.
For example, the new migraine drug Aimovig achieved 21% sales growth in the fourth quarter alone, with sales increasing 24% year-on-year to 378 million U.
S.
dollars; sales of osteoporosis drug Evenity soared 85% to 191 million U.
S.
dollars.

The biosimilar business also performed well.
Amgevita is a biosimilar of AbbVie's best-selling immunology drug Humira.
Its sales increased by 54% year-on-year to reach 331 million U.
S.
dollars.
It is the most prescribed biosimilar in Europe.
As more markets adopt biosimilars this year, Amgen expects growth to continue.

In other respects, Ann's imported anti-inflammatory drug Otezla performed well in 2020.
Even when COVID-19 caused a sharp slowdown in doctor visits, prescriptions for the drug increased by 13% during the year.

Amgen’s pipeline has two well-known first-of-its-kind drugs, which may help drive its future growth.
KRAS targeted inhibitor sotorasib is currently under FDA review, and the drug is being developed for the treatment of non-small cell lung cancer.
In addition, tezepelumab, a TSLP inhibitor in cooperation with AstraZeneca, recently released positive data in the treatment of asthma.

Regarding COVID-19, in September 2020, Amgen and Eli Lilly have cooperated to expand the production scale of antibody drug candidates for the treatment of COVID-19.
In December 2020, the company launched a clinical trial in cooperation with Takeda and UCB to determine whether three existing drugs, including Otezla, can suppress the dangerous inflammatory response experienced by some COVID patients.

14 Gilead Sciences

After setting a record of US$32.
6 billion in 2015, Gilead’s sales have continued to decline sharply in recent years, which shocked the company and its investors.
But in 2020, Gilead’s revenue data is $246.
9, an increase of 10% over 2019, indicating that the company’s free fall may eventually appear in the rearview mirror, at least for now.

Much of the surge last year can be attributed to the sudden success of COVID-19 drugs.
Gilead’s drug Veklury achieved sales of $2.
8 billion.

Although Gilead’s good luck with drugs was unexpected, the performance of its anti-AIDS drugs is not surprising.
Despite the challenges of GSK, Gilead still controls the AIDS market, with sales of its best-selling drug Biktarvy reaching US$7.
3 billion, an increase of 53% over 2019.
Part of the reason is that due to Biktarvy's dominance, sales of some of the company's other HIV drugs have declined, including Genvoya ($3.
3 billion) and various Truvada-based products ($2.
3 billion), which are facing new generic drug competition.
However, Descovy (US$1.
9 billion) and Odefsey (US$1.
7 billion) have achieved growth and have the potential for further growth.

All of these add up to Gilead’s HIV business with $16.
9 billion in sales, accounting for 69% of the company’s total revenue.
At the same time, not surprisingly, Gilead’s hepatitis C sales fell by 30% to $2.
1 billion, reflecting the development trend of these drugs over the past few years.

In 2020, Gilead seriously invested more than 27 billion US dollars in biotechnology investment, large and small.
The $21 billion acquisition of Immunomedics is the second largest M&A transaction in the company's history, and this acquisition brings promising breast cancer drug Trodelvy.
In addition, the blood cancer antibody drug magrolimab acquired by Forty Seven for US$4.
9 billion is expected to be launched next year.

15 Eli Lilly

Last year, Eli Lilly’s sales reached US$24.
54 billion, an increase of 10% from the US$22.
32 billion in 2019.
The company's COVID-19 antibody bamlanivimab brought in $871 million in the fourth quarter.
A large part of the company's growth is focused on increasing sales.
In general, last year the company's sales increased by 15%, but the actual price fell by 5%.

In addition to bamlanivimab, the drug launched by Eli Lilly in 2014 continued to bring growth to the company, accounting for about half of Eli Lilly's total sales last year.
These drugs include the type 2 diabetes drug Trulicity, which is its best-selling drug, as well as immunological blockbuster drug Taltz and migraine prevention drug Emgality.
Excluding Eli Lilly’s COVID-19 antibody therapy, the company’s global revenue increased by 6% last year.

At the same time, the company will perform outstandingly in the stock market in 2020.
Last year, Eli Lilly was one of the companies with the largest increase in the market value of pharmaceutical companies.
Investors increased the market value of Eli Lilly by 28% in 2020 to US$161.
5 billion.

Eli Lilly soon began researching drugs that could help fight COVID-19.
This work paid off: bamlanivimab was approved by the FDA last year and brought in considerable revenue.
The combined application of Bamlanivimab and another antibody, etesevimab, recently provided the strongest COVID-19 treatment data to date, reducing the risk of hospitalization and death by 87%.

Olumiant, a drug previously approved for the treatment of rheumatoid arthritis, also shows good prospects in the treatment of COVID-19.
In hospitalized patients who require supplemental oxygen or mechanical ventilation, the drug is used in combination with Gilead’s antiviral drugs and has won emergency approval from the FDA.

In addition to the current performance of the investment portfolio, the company has also released positive pipeline news in recent months.
Its Alzheimer's drug candidate donanemab announced its Phase 2 positive top-line results in January this year, but the complete data in March disappointed investors.
Eli Lilly’s diabetes drug candidate tirzepatide surpasses Novo Nordisk’s Ozempic in reducing blood sugar and weight loss, but analysts believe that Novo Nordisk’s drugs are still competitive in the market.

16 Boehringer Ingelheim

Although the COVID-19 pandemic caused a significant drop in the sales of countless drugs last year, BI not only managed to maintain a stable level, but also increased its revenue by 3% to $22.
29 billion.
According to the company's annual report, after deducting foreign currency factors, net sales increased by 5.
6% year-on-year.

This performance is largely attributable to its type 2 diabetes investment portfolio, especially its blockbuster product Jardiance.
Its sales in 2020 increased by 15% to US$2.
82 billion.
The drug’s sales in 2019 were approximately 2.
4 billion US dollars.
During the year, Jardiance followed in the footsteps of AstraZeneca’s competing product Farxiga and made great strides in heart failure, despite some setbacks in diabetes.

Another drug that will enable BI to achieve strong performance in 2020 is the idiopathic pulmonary fibrosis drug Ofev, with sales increasing by 38% to 2.
34 billion US dollars.
The company has sought to develop Ofev’s sales market in a series of extremely rare lung diseases, and in February passed the FDA’s expanded approval to treat a series of chronic fibrotic interstitial lung diseases (ILD) with progressive phenotypes.
patient.
BI said at the time that the approval covers 18%-32% of the total number of ILD patients, including about 200 diseases that may cause irreversible scarring of lung tissue.

At the same time, Boehringer's bet on China paid off in early 2020.
In January last year, the company's Chinese biopharmaceutical base became the first CDMO under the marketing authorization holder (MAH) system to produce an approved drug (BeiGene anti-PD-1 checkpoint inhibitor tislelizumab).

In 2017, BI started the first phase of its US$77 million plant in China, equipped with a single-use bioreactor capable of handling 2,000 liters of clinical supply or commercial production.
The design of the BI factory can also add an additional 2000 liters of disposable bioreactors and potting completion capacity as needed.

17 Novo Nordisk

In early 2020, Novo Nordisk focused on putting its highly anticipated oral hypoglycemic drug Rybelsus on the market.
The drug was approved by the FDA in September 2019, but the company did not immediately invest all its marketing efforts to support the launch of the product in the process of negotiating with the payer.
After the drug was put on the market, the COVID-19 pandemic struck.
Despite this, Rybelsus generated $300 million in revenue during its first full year of listing.

At the same time, sales of Novo Nordisk's injectable GLP-1 drug Ozempic soared in 2020.
The drug’s revenue last year was approximately US$3.
4 billion, surpassing the company’s older GLP-1 drug Victoza, which had approximately US$3 billion in revenue.
In 2019, Victoza's sales were almost twice that of Ozempic.

Outside of the key GLP-1 franchise, Novo Nordisk's insulin sales fell by 3% at a constant exchange rate, partly due to the realization of price reductions and the new legislation in the United States that forced the company to offer greater discounts to health insurance.
As fewer and fewer patients begin to receive treatment, the pandemic has also affected the growth of Novo Norton’s weight-loss drug Saxenda.

Looking to the future, Novo Nordisk recently announced strong data on Ozempic's treatment of obesity, which may have a fierce contest with Eli Lilly.
In Novo Nordisk's Phase 3 trial, Ozempic continued treatment for 68 weeks, and one-third of patients lost more than 20% of their weight.
Eli Lilly's tirzepatide also released impressive data, but analysts believe that Novo Nordisk Ozempic can still occupy a place in the market.

18 Tiva

In 2020, Teva achieved revenues of US$16.
7 billion, slightly lower than the US$16.
8 billion in 2019.
The company attributed the shortage to the continued decline in Copaxone, its best-selling drug for multiple sclerosis, and the decline in revenue from certain oncology and respiratory products.
In addition, COVID-19 has also had an impact on sales, which is not surprising.

However, the COVID-19 pandemic is not all bad for Teva.
The company benefited from its reserves of generic drugs and OTC products, with sales of $100 million in the first quarter.
In March, Teva promised to supply hydroxychloroquine to the United States, and provided approximately 16 million doses of hydroxychloroquine to hospitals across the United States.

During the Teva epidemic, it focused on two internal asset expansion plans.
After experiencing significant cost cuts, Teva will use the migraine drug Ajovy and Huntington treatment drug Austedo as potential sales drivers in 2020.
In February of that year, the estimated sales of these drugs in 2020 will reach 250 million US dollars and 650 million US dollars, respectively.

In January 2020, the Ajovy auto-injector was approved by the U.
S.
FDA to enter the market.
Teva reported that Ajovy's sales in North America surged by 50% in the second quarter.
In total, Ajovy generated $183 million in revenue in 2020.
Teva predicted in its full-year profit report that the drug's sales in 2021 may reach 300 million U.
S.
dollars.

Austedo's annual revenue was $638 million, which was close to expectations.
In 2021, sales of the drug may reach US$950 million.
However, in February 2020, due to the failure of a Phase 2/3 study of Austedo in the treatment of children with Tourette syndrome and a separate Phase 3 study, Teva's plan to expand the drug's indications was frustrated.

19 Bojian

Biogen's Alzheimer's disease drug aducanumab may become its future blockbuster product.
The drug failed in a 2019 trial, but was revived after in-depth analysis of the data.
Biojian has submitted aducanumab to the FDA for review, and the deadline is June.
This may be a huge victory for Bojian, who has been hurt by competitive pressure, or another major setback.

At the same time, in terms of business, Bojian will struggle in 2020.
The company’s global sales were US$13.
44 billion, down 6.
5% from the US$14.
38 billion in 2019.

In the competition between Roche and Novartis, the sales of Bojian's spinal muscular atrophy drug Spinraza fell slightly from US$2.
1 billion to US$2.
05 billion.

But in the long run, Bojian is counting on the continuous birth of new drugs in its pipeline.
In addition to aducanumab, the company is also developing candidate drugs for biosimilars, choroidal disease and stroke.
The company signed several development agreements last year to strengthen its pipeline, including a multi-billion dollar deal with Sage.

Bojian is also very active in the field of biosimilars: its biosimilars generated nearly $800 million in revenue last year, and the company may launch Lucentis biosimilars later this year.

20 Astellas

Thanks to industry consolidation in recent years, Astellas ranks 20th in 2020 with sales of more than 11 billion U.
S.
dollars.

In the first quarter of 2020, Astellas generated 312.
3 billion yen, or approximately 2.
87 billion U.
S.
dollars in revenue.
Then, for the rest of 2020, the company's sales reached 940.
9 billion yen, or 8.
63 billion U.
S.
dollars.
Together, global sales in 2020 will reach 11.
5 billion U.
S.
dollars.

Although COVID-19 has brought challenges to the company in 2020, Astellas did achieve some victories.
In February 2020, the company and Seattle Genetics (SeaGen)'s antibody conjugate Padcev achieved impressive results in the treatment of advanced bladder cancer, prompting SVB Leerink analyst Andrew Berens to expect the highest sales of the drug Increased to 5.
8 billion U.
S.
dollars.

Reference source: The top 20 pharma companies by 2020 revenue